Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ekf Diagnostics Holdings Plc LSE:EKF London Ordinary Share GB0031509804 ORD 1P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -1.40 -1.83% 75.00 74.40 75.00 75.60 73.20 75.60 179,608 16:11:10
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
Health Care Equipment & Services 65.3 15.4 2.5 30.6 341

Ekf Diagnostics Share Discussion Threads

Showing 3726 to 3749 of 3750 messages
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
DateSubjectAuthorDiscuss
24/7/2021
11:28
As predicted, PCR testing volumes has almost certainly increased and perhaps significantly, and (unfortunately) it appears it could stay at relatively high levels going forwards - UK lacks testing capacity to bring pingdemic to a swift end, ministers warned System will not easily be able to meet demand if relaxation of self-isolation rules brought forward, sources say By Ben Riley-Smith, POLITICAL EDITOR; Bill Gardner and Lizzie Roberts 23 July 2021 Even though the daily Covid case count has dipped in recent days, there are concerns in Whitehall that the dropping of almost all major restrictions earlier this week could trigger a new surge. The limits of testing – both PCR and lateral flow tests – are closely linked to the debate about when self-isolation rules can change. One source said that last week ministers ordered more lateral flow tests amid fears they would "run out" by around mid-August. The availability of PCR tests is also coming under pressure. Last week, the NHS admitted that turnaround times for testing in the community had "decreased substantially" since May. Official figures show that the percentage of tests processed within 24 hours fell sharply from 93 per cent in May to 64 per cent in the week ending July 14. A testing source said turnaround times could fall even further if the change to self-isolation rules was brought forward. They warned this could push processing times beyond 72 hours, when samples can go off and produce false negatives. "We are therefore calling on you to ensure that the necessary testing is in place to enable people who have been double vaccinated for longer than two weeks and pinged by the NHS Covid app, to immediately return to work, following a negative PCR test, rather than having to self-isolate.” A Department of Health and Social Care spokesman said: "The testing and tracing being delivered across the country is saving lives every single day and stopping the spread of the virus by breaking chains of transmission and helping to control outbreaks wherever they exist. "NHS Test and Trace has capacity in place to respond to increases in demand and people can have confidence that if they need a test, they can get one. Anyone who has Covid-19 symptoms can book home-testing PCR kits and more booking slots are made available at testing sites each day." Full story - hTTps://www.telegraph.co.uk/news/2021/07/23/uk-lacks-testing-capacity-bring-pingdemic-swift-end-ministers/ And with regard to a particular point raised in the above article that "this could push processing times beyond 72 hours, when samples can go off and produce false negatives." EKF has an answer to that, cue the attributes of PrimeStore MTM (even if its just in case any extension of the processing times waste the sample and extend the whole testing process further and exacerbating the situation!). It's also why Primestore MTM is effective in enabling downstream sequencing, despite any such delays. Note that EKF has already confirmed that supply contracts have be won with Public Health England, Private Labs and Universities in the UK and has a large contract with distributor to supply the Government of Ireland.
wan
24/7/2021
11:03
In my view, the broad-based strength this large player experienced in the first half provides a good guide/overview of the sector, with the full year outlook also providing a reassuring feature, and at the very least, complimenting the confidence announced by EKF's management in terms of the full year, and indeed the impact from the delivery of their growth strategy - Sciences and Diagnostics Businesses Jul 22, 2021 This story has been updated with information from Danaher's analyst conference call. NEW YORK – Danaher reported before the opening of the market on Thursday that its second quarter revenues rose 37 percent year over year, thanks largely to steep gains from its life sciences and diagnostics businesses. For the three months ended July 2, revenues rose to $7.22 billion from $5.30 billion in the second quarter of 2020, beating the average Wall Street analyst estimate for revenues of $6.72 billion. Revenues for the life sciences business rose 41 percent to $3.73 billion from $2.64 billion, revenues for the diagnostics business also rose 41 percent to $2.34 billion from $1.66 billion, and the company saw a 16 percent increase in the environmental and applied solutions business to $1.15 billion in revenue from $995.0 million in the year-ago quarter. "Broad-based strength across the portfolio helped us deliver over 30 percent core revenue growth and outstanding earnings per share growth and cash flow generation," Danaher President and CEO Rainer Blair said in a statement. "We continued to make significant growth investments during the quarter, strengthening our organic growth trajectory and enhancing our portfolio with the announcement of our pending acquisition of Aldevron." Danaher ended the quarter with $7.32 billion in cash and cash equivalents. For the third quarter, the company said it expects core revenue growth in the mid- to high-teens percent range. Blair said the company expects to deliver approximately 20 percent core revenue growth for full-year 2021. Danaher also expects to recognize $2 billion in COVID-related vaccine and therapeutic revenues in 2021 and anticipates entering 2022 with approximately $1.5 billion in COVID-related backlog revenue. He also noted the company expects to ship approximately 50 million respiratory tests in 2021. Full story - hTTps://www.360dx.com/business-news/danaher-q2-revenues-rise-37-percent-driven-life-sciences-and-diagnostics-businesses#.YPvVHo5KiF4
wan
23/7/2021
16:02
wrong thread
pugugly
23/7/2021
07:41
News coverage for the above report - Report calls for breakthrough diagnostics to be funded like new medicines 21 JULY 2021 The Future of Diagnostics Delivery in the UK report, which is backed by both the Institute of Biomedical Science (IBMS) and the Association of British HealthTech Industries (ABHI), is based on interviews with leading figures in Government, the NHS and UK pathology community. The findings highlight the clear discrepancy between the value diagnostics deliver to the health system and the investment it currently receives, and focuses on three key areas of development for strengthening the UK diagnostics sector of the future and improving patient access to diagnostic innovations: Expanding the size and profile of the NHS pathology service; Developing the future testing landscape; and Increasing the uptake of innovative diagnostics across care pathways. hTTps://www.med-technews.com/news/Medtech-Diagnostics-news/report-calls-for-breakthrough-diagnostics-to-be-funded-like-/
wan
23/7/2021
07:38
The pandemic has brought diagnostics into sharper focus. The following report and its recommendations are insightful and provides for a very worthwhile read - The Future of Diagnostics Delivery in the UK Roche Diagnostics Limited July 2021 The COVID-19 pandemic has demonstrated beyond any reasonable doubt the essential role that diagnostics play in the health of every citizen in this country. From prevention to disease management, diagnostic testing has always been vital to patient outcomes, with in vitro diagnostics informing 70% of all clinical decisions taken in the NHS. When we consider, however, that for every £100 spent in the NHS, only £1 will be invested in diagnostic testing, there is a clear discrepancy between the value the UK places on diagnostics, and our investment in them. This country is a global leader in clinical discovery and scientific excellence, and the NHS is world renowned for its workforce, safety and efficiency. Yet, the fact remains that for many major diseases, we fall behind other leading economies in terms of our outcomes. The historic lack of investment in diagnostics is, tragically, a key factor in this disparity, and one with far reaching consequences. When the pandemic hit in early 2020, we simply did not have the same diagnostic tools, assured supplies and infrastructure as other European countries to rapidly test for a novel virus. Since the start of the COVID-19 pandemic, so much has changed. We have seen unprecedented collaboration between the NHS, Government, the pathology sector and the diagnostics industry in the UK. New partnerships and ways of working have been forged to establish the rapid and effective testing infrastructure necessary to meet the scale and severity of the challenge we face. The focus on diagnostics may have historically come second to treatment, cures or vaccines, but the importance of testing in this global pandemic has proved beyond doubt its role as the cornerstone of every treatment pathway. This must now be the catalyst for a bigger conversation on how we address the wider impact of COVID-19 on health outcomes in the UK. Conclusion The essential role diagnostic innovations play in delivering improved outcomes, driving efficiencies and curbing outbreaks has long been recognised by the health system. However, they have never been embraced at the scale or speed needed to realise their true potential. 2020/21 has changed the approach of the NHS towards diagnostics for good. At a time when the world around us continues to change faster than ever before, we must not simply keep pace with this change, but show the world what can be done. As we look towards the next 12 months, Roche Diagnostics stands ready to continue to partner with Government, the NHS and the pathology professional bodies to realise the recommendations in this document and help create a diagnostics industry in the UK fit for the future. hTTps://dianews.roche.com/rs/106-RRW-330/images/The%20Future%20of%20Diagnostics%20Delivery%20in%20the%20UK%20report.pdf
wan
22/7/2021
17:31
No specific insight yet that I can recall, aside from indicating a target of one investment per year and one floatation per year. And according to the Growth Strategy, EKF continue to be in conversations with MSIP over future initiatives and they will look to update investors at the Interim Statement in September 2021 (page 13) - hTTps://www.ekfdiagnostics.com/res/EKF%20Investor%20Presentation%20June%202021%20Growth%20strategy%202021-2024.ppt.pdf
wan
22/7/2021
15:55
Yes they have.
tongosti
21/7/2021
16:04
Have shareholders been given any insight into future opportunities which may flow from the relationship with Mt Sinai?
chrysalis99
21/7/2021
11:33
Is all the diagnostics revenue classified as non-core or just the Covid-19 testing? As rivaldo points out, the latter seems likely to be ongoing for several years, with EKF hopefully continuing to gain significant revenue from this. As well as being useful revenue and profits, it will increase the scope for earnings enhancing acquisitions.
shanklin
21/7/2021
11:16
LOL - tongosti is obviously someone who waits to buy at the top ! I first invested here at 50p last August so in just under a year the value of my original holding has increased by 49%. Having subsequently added some more, my average cost is now 55.2p and therefore my current gain is circa 35%. Hardly a price that has been in limbo over that period. My "investor euphoria" has so far paid off well in comparison to his "gloom from the sidelines" approach !
masurenguy
21/7/2021
11:16
Thanks Welshborderer. I have a strictly personal view with regard to the share price, suffice to say it potentially sits north of £1, whilst collecting dividends on the way as well as benefiting from the opportunities generated from the partnership with Mount Sinai. It's therefore reassuring to read the albeit limited note above from Singer regarding the potential, hence I am looking forward to the delivery of early phases of the growth plan. Plus, I note we now have clarity regarding the growth plan being funded from current cash resources.
wan
21/7/2021
11:01
Today's Singer headlines to its research note: EKF recently unveiled a strategy for driving growth in the business over the next few years. It will be led by a refreshed executive management team and board, building on renewed strength in the core business and opportunities in developing wider contract development and manufacturing activities. Accretive bolt-on acquisitions will also be considered, all funded by the current strong net cash position of the group. Overall, the ambition is to deliver sustainable double-digit EBITDA growth into the medium term. This note takes a detailed look at the growth drivers and opportunities now in prospect. In addition to introducing conservative formal FY22 & FY23 estimates for the first time, we also look at a range of potential scenarios, one of which shows how EBITDA could reach £45.9m by FY24. Putting that on a multiple of 13- 15x implies a potential Enterprise Value of £597-688m, against a current EV of £314m. Successful delivery should therefore lead to material value creation. Does anyone have full access to this report?
welshborderer
21/7/2021
09:07
https://www.insidermedia.com/news/wales/first-half-revenues-soar-as-ekf-looks-ahead-with-confidence
mirandaj
21/7/2021
08:49
There is scope and indeed potential for further upgrades in my view. The managements conservative approach to forecasting and guidance to analysts is playing its part, which I am comfortable with, but the recent track record perhaps provides investors with better guidance than the current forecasts!
wan
21/7/2021
08:38
There must be scope for upgrading the forecasts for current year and year to June 22. According to my readings Sharescope 2022 showing EBITDA of £17m. They have done £12.75 in the first half of 2021. I note that the last note from Singers (may 2021) only had forecasts up to 2021 and suggested they would update forecasts for subsequent periods later this year. Anybody else got a view on the anomalies between management statements of double digit growth and current forecasts?
cgequityinvest
21/7/2021
08:18
Good update. The confidence already being shown in trading for the full year augurs well. I strongly suspect that COVID-19 sample collecting will be providing substantial revenues for some time to come, and certainly much longer than is assumed in the market forecasts out there which naturally have to be conservative in that respect. Worth noting that EKF now have around £33m of cash and liquid assets via shares with which to grow the business organically and via acquisition - around 10% of the total m/cap.
rivaldo
21/7/2021
08:00
wan, Current market forecasts certainly assume a surprising drop off in revenue, profit etc.
shanklin
21/7/2021
07:57
Another excellent trading update and confirmation that we are 'firmly' on course for the full year to be comfortably ahead of the already upgraded expectations. Given the managements conservative approach to forecasting and that the second half usually delivers a stronger performance compared to the first, it bodes well indeed for the full year outcome. And I am thus also very much looking forward to the managements delivery of the initial phases of EKF's 2021-2024 growth strategy.
wan
21/7/2021
07:09
Trading Update H1 2021 performance in-line with already upgraded management expectations Full year performance expected to be in-line with management expectations EKF Diagnostics Holdings plc (AIM: EKF), the AIM listed point-of-care business, provides the following trading update for the six months ended 30 June 2021. As previously announced in our AGM statement in May, the strong trading from the beginning of the year continued into the second quarter of 2021. This continues to reflect improving trading in the core business and ongoing strong demand for our contract manufacturing services for COVID-19 sample collection devices and associated kits. The Board remains confident that trading for the full year will remain strong and will be in-line with already materially upgraded management expectations. Revenues for the six months ended 30 June 2021 were GBP38.56m (H1 2020: GBP26.33m) and the Company expects to report adjusted EBITDA(1) in the region of GBP12.75m (H1 2020: GBP8.93m). Gross cash as at 30 June 2021 was GBP20.78m and cash net of borrowings was GBP20.39m, in-line with management expectations. In addition, the Company's interest in Renalytix plc (1,002,981 shares) had a fair value of GBP10.83m, and its Verici Dx plc securities (2,677,981 shares) had a fair value of GBP1.83m, based on closing mid-market prices on 30 June 2021. Following the payment of an inaugural cash dividend of 1p per share at the end of last year (in respect of 2019) the Company has confirmed its intention to maintain a modest but progressive dividend policy, and a further dividend payment to shareholders of 1.1p per ordinary share, which it proposes to pay on 1 December 2021 to shareholders on the register at the close of business on 5 November 2021. The ex-dividend date for this timetable is 4 November 2021. The Company remains confident that its growth strategy, as outlined to shareholders at the Annual General Meeting in May, will create a business which, aside from any COVID-19 related revenues, is capable of generating significant double-digit growth in adjusted EBITDA(1) over the next 3 to 4 years. The Board believe this can be achieved by: -- investing in the existing core business to drive strong organic growth; -- maximising value from the agreement with Mount Sinai Innovation Partners; -- seeking complementary and targeted earnings-enhancing acquisitions with key strategic value to the core business; -- continuing to maximise the opportunity to assist clients to control the impact of COVID-19, and to evolve new contract manufacturing capabilities in this area to a broader range of diagnostic and other healthcare settings. EKF expects to announce its unaudited results for the six months ended 30 June 2021 in the first half of September 2021, with the date to be confirmed in a subsequent announcement.
masurenguy
20/7/2021
08:55
A healthy opportunity? James Hester 18 hours ago While the coronavirus pandemic has put a huge spotlight on investment opportunities in the healthcare sector, it may also be worth considering growth prospects for the industry beyond COVID-19. Over the past 18 months, healthcare has shown its critical role in testing, therapeutics, vaccines and patient care. However, performance across healthcare stocks has varied greatly. Some firms have seen huge rises in revenue to reflect the take-up of their coronavirus-related solutions, while others have seen a revenue slump as patients have deferred non-COVID treatment or hospitals and clinics have postponed many non-emergency procedures. The easing of lockdowns means the other treatment areas are back on track, even as companies with coronavirus solutions still find a market for their products and services: vaccinations mean the world is learning to live with the disease though eradication is some way off. At the same time, businesses that have developed solutions in response to COVID-19 may also be able to further capitalise on these efforts by deriving non-coronavirus products from the same platforms. Doing good Laurie Don, investment manager at Liontrust, points to companies such as ThermoFisher Scientific and PerkinElmer in the US, which have been heavily involved in coronavirus testing, where revenues from COVID-related areas have grown more than enough to offset falls in other parts of their businesses that were shut or experienced a significant slowdown amid the pandemic. “Over the coming years, as the world recovers from and moves beyond COVID, we expect healthcare companies to continue to do well by doing good,” says Don. He singles out Swiss pharmaceutical giant Roche, which has seen significant demand for its diagnostic machines during the pandemic and is set to continue to expand its global footprint in this area. “Even as levels of COVID-19 testing fall, these machines will be put to work to scan for other serious diseases where governments have been less keen to invest the initial outlay, such as tuberculosis or hepatitis C,” comments Don. With countries heavily scarred by the pandemic, governments and individuals may be keener than ever to take a more proactive stance in monitoring and preventing disease before it occurs. Full article - hTTps://capital.com/a-healthy-opportunity
wan
19/7/2021
14:01
Investor presentation this Thursday @ 10am - https://investegate.co.uk/genincode-uk-ltd/rns/investor-presentation/202107190700085854F/ Matthew Walls, CEO and Paul Foulger, CFO will provide a live investor presentation via the Investor Meet Company platform at 10am BST on Thursday, 22 July 2021. The presentation is open to all existing and potential shareholders. Questions can be submitted pre-event via your Investor Meet Company dashboard up until 9am the day before the meeting or at any time during the live presentation. Investors can sign up to Investor Meet Company for free and add to meet GENinCode plc via:hxxps://www.investormeetcompany.com/genincode-plc/register-investor
gocanes
19/7/2021
14:00
Cardiovascular disease company, focused on clinically-proven genomic precision testing products, to seek admission to AIM through an IPO GENinCode plc, the cardiovascular disease ("CVD") risk assessment company focused on predictive genetics for the prevention of cardiovascular disease, is delighted to announce its intention to seek admission of its issued and to be issued Ordinary Shares to trading on AIM, a market of the London Stock Exchange plc ("Admission"). On admission, the Company is expected to have a market capitalisation of approximately £42 million. The Company's product portfolio draws on genomic precision testing using polygenic (multiple-genes) technology, advanced molecular testing, genotyping and sequencing. Through a simple blood or saliva sample, the Company can analyse a patient's medical information and genetic variants associated with CVD to determine a Genetic Risk Score which is used for the subsequent assessment of a patient's cardiovascular disease risk. The Company also provides risk assessment for thrombosis (genetic predisposition to blood clotting). The Company's SITAB system, a proprietary software, bioinformatics and algorithmic platform with online cloud-based reporting, is used to process and record test results and genetic information using algorithms and artificial intelligence to assess a patient's risk of a cardiovascular event. SITAB reports results directly via a web portal to healthcare practitioners, cardiologists and physicians, in a user-friendly format. The current standard of care for primary prevention and assessment of the risk of CVD has been in use and largely unchanged for many years. It is based on risk assessment equations which evaluate 'classic' or 'traditional' cardiovascular risk factors such as age, gender, smoking, blood cholesterol levels and blood pressure among other factors for the onset of CVD. The equations enable physicians to categorise patients as being at low, moderate or high risk of a CVD event, usually over the subsequent 10-year period or sometimes using a 'lifetime' horizon from which the patient is then assessed for lifestyle changes or treatment. It is recognised that these 'classic' or 'traditional' risk assessments are imperfect with events not infrequently occurring in those individuals categorised at 'low' or 'intermediate' risk. The advent of genetic risk assessment for CVD is now able to help identify and reclassify those individuals traditionally categorised in the 'low' or 'intermediate' risk populations who are at higher genetic risk of a CVD event than their current standard of care risk assessment suggests. This enables earlier in life preventative measures to be adopted to lower the future risk of a CVD event. With CVD mortality levels continuing to rise globally, there is an increasing need for cardiologists to apply genetics to help advance patient prognosis and diagnosis to treat the onset of CVD. The Company's products combine predictive models of genetics and patient data using classic cardiovascular risk factors (CVRFs) and are designed to improve predictive capability and genetic risk assessment to provide a personalised and thereby tailored treatment pathway. Recent studies and scientific reports show the correlation between genetic load/burden and the onset of CVD. The Directors believe that GENinCode's technology is at the forefront of genetic risk assessment in the CVD space. The Company's key products are CE-Marked with the core products Cardio inCode and Thrombo inCode having IP protection in the major growth markets of Europe, the UK and the United States. The Company has now commenced its commercial expansion programme in Europe, the UK and the United States. On 28 April 2021, the Company announced a partnership to provide genetic testing from labs based at Royal Brompton and Harefield Hospitals. Following this, it was announced on 14 June 2021 that a product commercialisation agreement had been entered into with EVERSANA in the US. The Directors believe that the partnership with EVERSANA, a leading provider of global commercial services to the life science industry, will provide a significant opportunity for the Group to progress its commercialisation plans for the US. The Company's commercialisation strategy in the US is a significant part of GENinCode's long-term growth and commercial strategy. The Directors expect Cardio inCode to be reviewed by the FDA as a De Novo device. The Company submitted an initial application to the FDA in February 2021 for Breakthrough Device designation for its Cardio inCode product. The FDA review is ongoing with a decision expected in Q3 2021.
gocanes
19/7/2021
10:52
9 months and counting - still in sideways mode. Not worth committing capital (yet) to a lifeless stock UNLESS the market gives us the green light first. Hard as it is in practice - patience wins the day. Good week chaps (and chapesses).
tongosti
19/7/2021
08:13
As predicted, (unfortunately) PCR testing requirements will need to go into overdrive to cope - 4 hours ago - Covid test delays hamper England’s battle against new wave Public health leaders battling to contain a rising tide of Covid-19 infections in England are being hampered by delays in accessing and processing PCR tests, even as the country lifts its last pandemic restrictions. A surge in numbers seeking a test is expected after all remaining social restrictions were ended on Monday and self-isolation rules eased, in favour of regular testing, from August 16. The Department of Health and Social Care said testing and tracing was “saving lives every single day and stopping the spread of the virus by breaking chains of transmission and helping to control outbreaks wherever they exist”. Anyone who had Covid symptoms could book home-testing PCR kits “and more booking slots are made available at testing sites each day”. People familiar with the situation said NHS Test and Trace was ramping up laboratory operations and the Leamington Spa lab would eventually be able to process hundreds of thousands of Covid tests every day. It was also exploring options to increase capacity at other labs across the network, as well as commercial labs. Full story FT.com - hTTps://www.ft.com/content/e79bf9c9-894a-4556-abb8-8ffb350831b9
wan
Chat Pages: 150  149  148  147  146  145  144  143  142  141  140  139  Older
ADVFN Advertorial
Your Recent History
LSE
EKF
Ekf Diagno..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20210724 16:26:09